Rxivist logo

Role of hypothalamic MAPK/ERK signaling in diabetes remission induced by the central action of fibroblast growth factor 1

By Jenny M. Brown, Marie A. Bentsen, Dylan M. Rausch, Bao Anh Phan, Danielle Wieck, Huzaifa Wasanwala, Miles E. Matsen, Nicole E. Richardson, Xin Zhao, Peng Zhai, Anna Secher, Gregory J Morton, Tune H Pers, Michael W. Schwartz, Jarrad M Scarlett

Posted 25 Dec 2020
bioRxiv DOI: 10.1101/2020.12.24.424313

The capacity of the brain to elicit sustained remission of hyperglycemia in rodent models of type 2 diabetes following intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) is well established. Here, we show that following icv FGF1 injection, hypothalamic signaling by extracellular signal-regulated kinases 1 and 2 (ERK1/2), members of the mitogen-activated protein kinase (MAPK) family is induced for at least 24h. Further, we show that in diabetic Lepob/ob mice, this prolonged response is required for the sustained antidiabetic action of FGF1, since it is abolished by sustained (but not acute) pharmacologic blockade of hypothalamic MAPK/ERK signaling. We also demonstrate that FGF1 R50E, a FGF1 mutant that activates FGF receptors but induces only transient hypothalamic MAPK/ERK signaling, fails to mimic the sustained glucose lowering induced by FGF1. These data identify sustained activation of hypothalamic MAPK/ERK signaling as playing an essential role in the mechanism underlying diabetes remission induced by icv FGF1 administration.

Download data

  • Downloaded 244 times
  • Download rankings, all-time:
    • Site-wide: 108,277
    • In neuroscience: 16,571
  • Year to date:
    • Site-wide: 34,752
  • Since beginning of last month:
    • Site-wide: 49,645

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide